Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Atara Biotherapeutics Stock Quote

Atara Biotherapeutics (NASDAQ: ATRA)

Price as of April 24, 2024, 12:45 p.m. ET

Atara Biotherapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
ATRA -75.56% -97.85% -53.60% -94%
S&P +22.56% +73.28% +11.62% +169%

Atara Biotherapeutics Company Info

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

News & Analysis


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.